Airiver Medical, a clinical stage company developing technologies to help patients with certain respiratory tract conditions, said on Wednesday that it has received investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA), enabling the company to begin a pivotal clinical trial of the Airiver Pulmonary Drug Coated Balloon (DCB) to treat central airway stenosis.
This is Airiver's first IDE study submission and approval.
Planned to enrol up to 200 patients with central airway stenosis, the study aims to assess the safety and efficacy of the Airiver DCB, which combines standard balloon dilation to open the respiratory tract with proprietary drug delivery designed to maintain symptom relief and prevent recurrence.
The proprietary coating allows for very localised paclitaxel delivery to the stenosis, while limiting levels in the surrounding healthy tissue.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval